Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma

Haifeng Wan†, Shan Lu†, Lin Xu, Kefei Yuan, Yang Xiao4, Kunlin Xie† and Hong Wu†

1 Department of Liver Surgery and Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China, 2 Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China, 3 Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China, 4 Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu, China

Object: The prediction of hepatocellular carcinoma (HCC) prognosis faced great challenge due to tumor heterogeneity. The purpose of this study was to explore the correlation between the immune infiltrate and prognosis. Moreover, we aimed to establish a risk prediction model for survival in HCC patients based on clinicopathological and immune indicators.

Methods: In this study, 316 patients with HCC who underwent radical resection in West China Hospital from 2009 to 2014 were included. Clinicopathological data and pathological specimens were collected. H&E staining and immunohistochemical staining were performed on the pathological tissue sections. The evaluation of tumor-infiltrating lymphocyte (TIL) density was based on H&E slices, and the assessment of the expressions of CD8, CD66b, Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin domain and mucin domain-3 (TIM-3), Programmed Cell Death Protein 1 (PD-1), Programmed Cell Death Ligand 1 (PD-L1), OX40, CD68b, and Tryptase, was performed on the immunohistochemical slices. A risk prediction model for survival in HCC patients was established by integrating immune-related biomarkers and clinicopathological indicators.

Results: The Barcelona Clinic Liver Cancer (BCLC) stage; the microvascular invasion status; the density of TILs; the expressing levels of CD66b, OX40, and PD-L1 in the immune cell; CD68; and CD8 were the predictors of patients’ overall survival (OS). The BCLC stage; the density of TILs; and the expressions of OX40, CD68, and CD8 were associated with disease-free survival (DFS). The expressions of CD66b, CD68, OX40, and CD8 had a cumulative effect on prognosis. The area under the curve of the prediction model for OS based on clinicopathological features was improved from 0.62 to 0.74 by adding to CD8, OX40, CD68, CD66b, and TILs, whereas it was improved from 0.59 to 0.73 for the DFS prediction model.

Conclusion: Our results, if confirmed, indicated that immune-related biomarkers should be taken into account or stratified in survival analysis for HCC.

Keywords: hepatocellular carcinoma, immune-related biomarkers, survival, prediction, prognostic model
INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor and the fourth leading cause of cancer-related death worldwide (1). Although a comprehensive strategy consisting of surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), and targeted therapy applied to HCC patients has shown its therapeutic efficacy in curbing overall mortality from this disease, the recurrence and mortality remain an escalating trend in many countries, and the advanced stage is the predominant state of HCC patients in many parts of the world (2). More attention should be paid to patients at high risk of recurrence in order to improve patients’ overall survival (OS) (3, 4). An integrated prognostic predicting system for HCC patients who underwent radical resection may facilitate patient stratification and individualized follow-up planning.

In the past decades, several prognostic models based on clinicopathological data such as the Japan Integrated Staging score (5), the Cancer of the Liver Italian Program score (6), and the Barcelona Clinic Liver Cancer (BCLC) staging system (7) have been proposed for HCC and widely accepted. However, there is no consensus regarding the optimal tool for prognosis stratification.

The tumor immune microenvironment, determined by the density, composition, functional state, and organization of the leukocyte infiltrate of the tumor, is a focus in the studies of tumor immunology (8, 9). The commonly investigated subsets of leukocytes in the tumor immune microenvironment include T cells, B cells, natural killer cells, tumor-associated macrophages (TAMs), neutrophil leukocytes, and even mast cells. Accumulating evidence suggests that different leukocyte subsets have different impacts on tumorigenesis and immune response, indicating different outcomes. For example, CD8+ T cells constitute the most powerful immune attack against tumors and higher tumor infiltration of CD8+ T cells showed a significant advantage in OS or DFS (10–12), whereas it is reported that T regulatory cells (Tregs) were associated with worse survival in gastrointestinal tumors (13–15). An elevated neutrophil ratio showed poor survival (16, 17), and high infiltration of TAMs was correlated with tumor recurrence and shorter survival due to the possible suppression of effective anticancer immunity, the stimulation of angiogenesis, and tissue remodeling (18, 19). Mast cells are another subset of immune cells, which were reported to accumulate in both solid and hematologic tumors. The consequences of their presence in the tumor immune microenvironment still remain unclear (20–22). In recent years, immune checkpoint therapy has been widely used to treat malignant cancers (23–25). Immune checkpoints such as Programmed Cell Death Protein 1 (PD-1), T cell immunoglobulin domain and mucin domain-3 (TIM-3), and Lymphocyte activation gene-3 (LAG-3), which are often activated in the tumor tissue and regulate T-cell function, are important immunotherapy targets (26–28). PD-1 inhibitors have shown promising clinical effects in the treatment for HCC (29).

In the present study, we aimed to identify the immune-related predictors for HCC patients after curative resection and analyzed their effects on OS and disease-free survival (DFS). Furthermore, we tried to establish a novel risk prediction model for survival in HCC patients based on clinicopathologic and immune variables, aiming at improving the management of high-risk groups.

MATERIALS AND METHODS

Patients and Samples

The research protocol was approved by the local ethics committee of West China Hospital (2019788), and written informed consent was provided in this study. From 2009 and 2014, consecutive patients who fulfilled the following inclusion criteria were enrolled: a) age ≥ 18 years and ≤70 years and b) had surgically confirmed HCC and underwent radical resection. Patients were excluded if they: a) had any preoperative anticancer treatments for HCC; b) had any postoperative systemic anticancer treatments for HCC; c) had a history of other malignant tumors; and d) died within 2 weeks postoperatively due to any complication.

The sample collection was as previously described (32). Briefly, approximately 5-g surgical specimens of tumor and adjacent tissue were isolated once resected and immediately stored in liquid nitrogen until analysis. Tissue cores were punched from the representative tissue areas of HCC samples that were fixed by formalin and embedded by paraffin orderly and arranged in 1 recipient paraffin block, which was cut into 5-mm sections.

Data Collection

Clinical and biological data, including age, gender, hepatitis B and C status, and the serum alpha-fetoprotein (AFP) level were obtained before operation from an electronic clinical database for analysis. The Barcelona Clinic Liver Cancer (BCLC) staging system was used to evaluate tumor staging at the time of each patient’s diagnosis. Histological slides were reviewed for the tumor size, number, differentiation, vascular invasion, and the Ishak fibrosis score of the adjacent liver tissue by a pathologist specializing in hepatobiliary pathology and tumor characteristics.

Follow-up

All patients were followed up after surgery at 1 month, every 3–6 months thereafter with serum AFP and ultrasound, contrast-enhanced CT, and/or contrast-enhanced MRI. The primary endpoint was OS, defined as the time from surgery to death regardless of the cause. The secondary end point was DFS, defined as the interval between surgery and the detection of recurrence or death from any cause. Patients with no events were censored at the time of their last follow-up.

Hematoxylin and Eosin Stain and Immunohistochemistry

H&E stain and immunohistochemistry were performed according to standard protocols detailed in previous studies (32, 33).
primary antibodies used for immunohistochemistry (IHC) contained the T-cell marker of CD8; the macrophage marker of CD68; the Treg marker of OX40; the neutrophil marker of CD66b; the mast cell marker of Tryptase; and the immune checkpoints of PD-1, PD-L1, TIM-3, and LAG3. The details are shown in **Table S1**. The NDP.view.2 software program was used to view and capture the images for analysis.

**Pathologic Evaluation**

Pathologic evaluation was conducted by two liver pathologists blinded to clinical data. The quantitative assessment of TILs in tumor stromal was carried out on H&E-stained slides with 100 times magnification according to International TILs Working Group criteria (34). The full section was scanned for assessment except in areas with crush artifacts, necrosis, and regressive hyalinization. A full assessment of average TILs in the tumor area was used. Additionally, the scores were further classified into low (TILs < 10%) and high (TILs ≥ 10%)-TIL groups (**Figure 1A**).

As described in a previous study (32), five random images at 400 times magnification for each immune-stained slice were used for IHC evaluation. In brief, the bleeding areas, necrotic areas, marginal areas of non-specific staining, and non-tumor cell areas were excluded firstly. The tumor areas were then divided into a number for regions and numbered with Arabic numbers on scanning slice. Five random numbers were generated using Excel software to select five corresponding areas for quantitative assessment. The measurements for CD8, CD68, PD-1, TIM-3, LAG3, OX40, CD66b, and Tryptase were recorded as the total number of positive-expressing cells. The expressions of these immune-related markers were categorized into the high group, defined as the number of positive immune cells superior to the median of the full series, and the low group, defined as the

---

**FIGURE 1**  | **(A)** Representative images of high (left) or low (right) density of tumor-infiltrating lymphocytes (TILs) in the stromal of hepatocellular carcinoma on H&E-stained tumor sections (×100). **(B)** Representative immunohistochemistry images of high (left) or low (right) expression of immune-related biomarkers (×400). TILs, tumor-infiltrating lymphocytes.
RESULTS

Characteristics of Study Populations

A total of 316 patients fulfilling the inclusion and exclusion criteria were enrolled in this study. The baseline characteristics of the patients are summarized in Table S2. All patients were from China, and there were 258 men, accounting for 81%. The median follow-up time was 34 months (range 1–93 months).

Prognostic Value of Immune-Related Features

The results of the univariate logistic regression analysis of the immune-related biomarkers are shown in Table S3. TILs density, expressions of CD66b,OX40, CD68 and CD8 were associated with OS. TILs density and expression of OX40 were associated with DFS. Additionally, all these factors with a P-value less than 0.2 were selected for the multivariate analysis with the BCLC stage and MVI status, which were generally accepted as prognostic factors for HCC. In the multivariate analysis, the BCLC C stage; the MVI status; the BCLC stage, tumor differentiation, MVI status, and cirrhosis status, which were generally accepted as prognostic factors for HCC. The multivariate analysis results that high expression of CD66b, CD68, or OX40 and low expression of CD8 were risk factors for both OS and DFS, the participants in this study were further categorized into five groups by the number of these risk factors. The survival curves showed that the group with no risk factor had the best OS, which declined with an increasing number of risk factors. A similar result was observed for DFS (Figure 2).

CD8:OX40 Ratio was Associated With Hepatocellular Carcinoma Prognosis and Clinicopathologic Features

The prognostic values of CD8 and OX40 in our study were in accordance with previous studies (32, 36, 37). The prognostic relevance of the ratio of CD8/OX40 was investigated. We observed that the high-ratio group (CD8<sub>high</sub>/OX40<sub>low</sub>) and intermediate-ratio group (CD8<sub>high</sub>/OX40<sub>high</sub> or CD8<sub>low</sub>/OX40<sub>low</sub>) had better OS (high-ratio group HR=0.10, 95% CI=0.04–0.21, intermediate-ratio group HR=0.25, 95% CI=0.16–0.39, P<0.01) and better DFS (high-ratio group HR=0.21, 95% CI=0.11–0.39, intermediate-ratio group HR=0.33, 95% CI=0.20–0.56, P<0.01) compared to the low-ratio group (CD8<sub>low</sub>/OX40<sub>high</sub>) (Table 2, Figure 3). Further analysis indicated that the high-ratio group was associated with a higher AFP level (>400 ng/ml), an MVI-positive status, multiple tumors, and a smaller tumor diameter (median = 4 cm) in comparison to the low-ratio group (Table 3).

Prognostic Model Establishment and Assessment

The base model of risk prediction for OS was established using the well-known clinicopathologic prognostic variables including the BCLC stage, tumor differentiation, MVI status, and cirrhosis status, with an area under the curve (AUC) of 0.62. Five novel predictions were built by adding predictive immune-related biomarkers successively selected from the aforementioned analysis, containing CD8, OX40, CD68, CD66b, and TILs to the base model. Model 2 was based on the base model and immune-related biomarker of CD8; Model 3 was based on the base model and immune-related biomarkers of CD8 and OX40 together. Like this, model 5 was constructed based on the base model and CD8, OX40, CD68, CD66b, and TILs to the base model one by one. The AUC values were 0.67, 0.69, 0.70, 0.71, and 0.74, respectively (Figure 4A). The model 5 inputs including 4 clinicopathologic variables and 5 immune-related biomarkers for OS resulted in the highest AUC value of 0.74. The base model for DFS was also established based on the BCLC stage, tumor differentiation, MVI status, and cirrhosis status, with an AUC of 0.59. Meanwhile, four novel prediction models were developed by adding the immune-related biomarkers of CD8, OX40, CD66b, and TILs to the base model one by one. The AUC values were 0.59, 0.64, 0.67, and 0.73 respectively (Figure 4B). The model 4 inputs...
containing both 4 clinicopathologic variables and 4 immune-related biomarkers for DFS turned out the highest AUC value of 0.73.

**DISCUSSION**

In this study, we examined the relationship between the individual immune subset of the infiltrates in the HCC microenvironment and patients’ mortality. As is known, the CD8+ T cell, serving as the main effector cell, played a crucial role in antitumor immunity (38). Conversely, OX40+ Tregs exerted a strong immunosuppressive function, especially in collaboration with other immunosuppressive cells, such as macrophages and dendritic cells, leading to the depletion of T cells (39–41). Our results observed positive and negative associations of CD8+ T cell and OX40+ Tregs, respectively, with OS and DFS. Moreover, we tested whether the ratio of CD8 and OX40 was associated with the clinicopathologic parameters. We did find that the ratio of

| Variables | OS | DFS |
|-----------|----|-----|
| BCLC Stage | | |
| A | 218(78.4) | 61(28.0) | 1.00 | 0.09 | 121(73.3) | 63(52.1) | 1.00 | 0.04 |
| B | 47(16.9) | 19(40.4) | 1.63 (0.92–2.87) | <0.01 | 31(18.8) | 21(67.7) | 1.75(1.04–2.95) | 0.02 |
| C | 13(4.7) | 10(76.9) | 3.30 (1.56–6.99) | | 13(7.9) | 12(92.3) | 2.30(1.16–4.55) | |
| MVI | | |
| No | 219(69.3) | 56(25.6) | 1.00 | 0.05 | 219(69.3) | 63(28.8) | 1.00 | 0.25 |
| Yes | 97(30.7) | 43(44.3) | 1.58 (1.00–2.49) | | 97(30.7) | 43(44.3) | 1.28(0.84–1.96) | |
| TILs | | |
| Low | 175(55.6) | 70(40.0) | 1.00 | <0.01 | 103(56.3) | 80(77.7) | 1.00 | <0.01 |
| High | 140(44.4) | 29(20.7) | 0.39 (0.25–0.63) | | 103(56.3) | 80(77.7) | 0.29 (0.18–0.48) | |
| CD66b | | |
| Low | 149(50.0) | 30(20.1) | 1.00 | <0.01 | 99(53.8) | 50(50.5) | 1.00 | <0.01 |
| High | 149(50.0) | 62(41.6) | 1.89 (1.19–3.00) | | 99(53.8) | 50(50.5) | 2.80 (1.74–4.50) | |
| OX40 | | |
| Low | 180(57.0) | 39(21.7) | 1.00 | <0.01 | 96(53.8) | 50(50.5) | 1.00 | <0.01 |
| High | 136(43.0) | 60(44.1) | 3.52 (2.20–5.60) | | 96(53.8) | 50(50.5) | 2.80 (1.74–4.50) | |
| PD-L1 immune | | |
| Negative | 236(81.1) | 71(30.1) | 1.00 | <0.01 | | |
| Positive | 55(18.9) | 23(41.8) | 2.13 (1.25–3.63) | | | |
| PD-1 | | |
| Low | 272(86.3) | 89(32.7) | 1.00 | 0.21 | | |
| High | 43(13.7) | 10(23.3) | 0.62 (0.29–1.31) | | | |
| LAG3 | | |
| Low | 178(57.0) | 48(27.0) | 1.00 | 0.44 | 95(52.5) | 52(54.7) | 1.00 | 0.75 |
| High | 134(43.0) | 51(38.1) | 1.20 (0.76–1.88) | | 86(47.5) | 54(62.8) | 1.07 (0.69–1.67) | |
| CD68 | | |
| Low | 159(50.8) | 37(23.3) | 1.00 | 0.02 | 85(46.7) | 43(50.6) | 1.00 | 0.01 |
| High | 154(49.2) | 62(40.3) | 1.75 (1.10–2.78) | | 85(46.7) | 43(50.6) | 1.74 (1.12–2.88) | |
| CD8 | | |
| Low | 157(50.3) | 65(41.4) | 1.00 | <0.01 | 77(42.5) | 48(62.3) | 1.00 | <0.01 |
| High | 155(49.7) | 33(21.3) | 0.28 (0.17–0.44) | | 104(57.6) | 58(55.8) | 0.51 (0.33–0.80) | |

No, number; HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; BCLC Stage, Barcelona Clinic Liver Cancer Stage; MVI, microvascular invasion; TILs, tumor-infiltrating lymphocytes.
CD8:OX40 was relevant to the AFP level, MVI-positive status, tumor number, and tumor diameter, which were identified as the risk factors for survival in another study (42). The intensity of TILs serving as a biomarker regardless of the intricate heterogeneity of subsets was also an attempt for prognostic assessment. The TIL assessment was kept to the criteria proposed by the International TILs Working Group. In line with other solid tumors such as esophageal cancer and melanoma (43, 44), TIL intensity was proven effective for prognosis prediction for HCC. The classification of the percentage of TILs in our study was slightly different from the method proposed by the International TILs Working Group. As the number of patients with TIL intensity above 50% was too small, we combined those with TIL intensity between 10% and 50% and those higher than 50%, which were categorized as intermediate- and high-TIL groups, respectively, by the International TILs Working Group, into one group. The result that higher TIL density was in favor of survival was consistent with the results in breast cancer and non-small cell lung cancer studies (45, 46). A possible explanation could be that TIL infiltration was more likely to occur in tumors that are more immunogenic (47, 48).

We identified a prominent accumulative negative effect on prognosis as the number of risk factors increased. A possible explanation could be the synergistic effects of different subsets of infiltrate. CD68 and CD66b were generally expressed on the TAMs and neutrophils, respectively. There was plenty of evidence suggesting that both of them could promote neovascularization and were associated with tumor invasion and metastasis (49–52). The depletion of T cells caused by these immunosuppressive cells could also be a reason for the associated poor prognosis (39–41). The role of tryptase, a marker of mast cells, in tumors remains controversial. Some studies have shown that mast cells infiltrated in the tumor microenvironment...
were associated with a poor prognosis (53–55). Others have indicated that mast cells contain a variety of pro-inflammatory mediators. Additionally, the unique ability to prestore and release potentially beneficial anticancer mediators such as tumor necrosis factor α (TNF-α) and the granulocyte–macrophage colony-stimulating factor, mediating the necrosis of cancer cells (56–58), is prognostic. However, the fact that a prognostic value of tryptase was not observed in our study may be related to limited cases and missing immunohistochemical data in some cases. In addition, PD-1, TIM-3, and LAG3 did not have independent prognostic significance in our study, which may not limit their potential roles as predictive biomarkers for prognosis.

The concept of immune contexture, representing the preexisting immune parameters associated with patient survival, was generally accepted. The immune contexture can be leveraged not for therapeutics but rather for classification purposes (31), whereas the traditional alternative cancer classification modalities are still in use due to the poor exploitation of the immune contexture. In this study, we investigated the prognostic value of the immune features, identified the significant immunologic risk factors, and developed a prediction model for HCC based on both clinicopathologic and immune cell infiltrate subsets. We did find that the prognostic predictions integrating clinicopathologic and immune-related variables could improve the discrimination. This model is a tool for prognosis risk stratification and can be used to determine survival prognosis, which can assist clinicians in drawing up comprehensive treatment plans for patients and provide scientific assistance for surgical prognosis preliminary judgment and a basis for adjuvant therapy. It has clinical significance for prognosis prediction and a personalized management of HCC patients.

There are several limitations to our study. First, although our models demonstrated a relatively excellent discriminatory ability, external confirmation is needed. The similar results in one or more different cohorts, especially with a large population, are able to enhance the reliability of our finding. Second, our study did not document the prognostic meaning of some other immune-related markers. However, we have investigated those reported to play a significant role in HCC.

In summary, integrating immune-related biomarkers based on the clinicopathologic model can improve the risk-predictive performance for survival in HCC patients, indicating that immune-related biomarkers should be taken into account or stratified in survival analysis for HCC.

**FIGURE 3 |** Kaplan–Meier analysis of OS (A) and DFS (B) for CD8+/OX40+ TIL ratio. OS, overall survival; DFS, disease-free survival; TILs, tumor-infiltrating lymphocytes.

**TABLE 3 |** Association between the CD8+/OX40+ ratio and clinicopathological parameters.

|                | CD8\text{low}/OX40\text{high} | CD8\text{high}/OX40\text{high} or CD8\text{low}/OX40\text{low} | CD8\text{high}/OX40\text{low} | P     |
|----------------|-------------------------------|-------------------------------------------------------------|--------------------------------|-------|
| AFP>400(ng/ml) | 25/51(49%)                    | 117/187(62.6%)                                              | 56/73(23.3%)                   | <0.01 |
| MVI            | 26/52(50%)                    | 58/187(31%)                                                 | 12/73(16.4%)                   | <0.01 |
| No. of tumor>1 | 15/48(31.3%)                  | 25/161(15.5%)                                               | 10/62(16.1%)                   | 0.04  |

Data are no. of patients (%) unless otherwise indicated.

No., number; AFP, alpha-fetoprotein; MVI, microvascular invasion.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by ethics committee of West China Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

HW, HFW, and KX designed the experiments. HFW, KX, and LX performed the experiments. HFW and SL collected the clinical data. HFW, KX, and SL analyzed the data and made the figures. All authors wrote and revised the manuscript. HW proposed the study concept, supervised the research, and acquired funding for the study. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Key Technologies R&D Program (2018YFC1106800), the National multidisciplinary collaborative diagnosis and treatment capacity building project for major diseases (TJZ202104), the Natural Science Foundation of China (82173124, 82173248, 82103533, 82002572, 82002967, 81972747, and 81872004), the fellowship of China National Postdoctoral Program for Innovative Talents (BX20200225, BX20200227), the China Postdoctoral Science Foundation (2021M692278, 2020M673231), the Science and Technology Support Program of Sichuan Province (2021YJ0436), the Postdoctoral Science Foundation of Sichuan University (2021SCU12007), the I.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC18008), and the Postdoctoral Science Foundation of West China Hospital (2020HXBH075, 2020HXBH007).

ACKNOWLEDGMENTS

The authors would like to express special thanks to West China Biobanks, Department of Clinical Research Management, West China Hospital, Sichuan University for their support of human tissue samples and the Pathology Department for their help with pathologic evaluation.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.925362/full#supplementary-material

FIGURE 4 | Discriminatory accuracy of the models for OS (A) and DFS (B). Base model was based on the BCLC stage, differentiation, MVI status, and cirrhosis status; model 2 to model 5 were built by adding predictive immunologic variables of CD8, OX40, CD68, CD66b, and TILs successively for OS. Model 2 to model 4 were built by adding the predictive immunologic variables of CD8, OX40, CD66b, and TILs successively to the base model for DFS. OS, overall survival; DFS, disease-free survival; AUC, area under the curve; BCLC stage, Barcelona Clinic Liver Cancer stage; MVI, microvascular invasion; TILs, tumor-infiltrating lymphocytes.
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492

2. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2017) 3:524–48. doi: 10.1001/jamaoncol.2016.5688

3. Meniconi RL, Komatsu S, Perdigao B, Fiolle PY, Soubrane O, Scatton O. Recurrent Hepatocellular Carcinoma: A Western Strategy That Emphasizes the Impact of Pathologic Profile of the First Resection. Surgery (2015) 157:454–62. doi: 10.1016/j.surg.2014.10.011

4. Tabrizian P, Jibara G, Shrago B, Schwartz M, Roayaie S. Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis. Ann Surg (2015) 261:947–55. doi: 10.1097/sla.0000000000000710

5. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: The JIS Score Compared With the CLIP Score. Hepatology (2004) 40:1396–405. doi: 10.1002/hep.20486

6. Daniele B, Pignata S, Cremona F, Izzo F, Parisi V, Fiore E, et al. Prospective Validation of the CLIP Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology (2000) 31:840–5. doi: 10.1033/he.2000.5268

7. Llovet JM, Fuster J, Bruix J. The Barcelona Approach: Diagnosis, Staging, and Treatment of Hepatocellular Carcinoma. Liver Transpl (2004) 10:115–120. doi: 10.1002/it.20034

8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science (2006) 313:1960–4. doi: 10.1126/science.1129139

9. Binnwieser M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Ann Oncol (2015) 61:1957–67. doi: 10.1093/annonc/mdu330

10. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association of Systematic Reviews and Meta-Analyses of Observational Studies. Neutrophil to Lymphocyte Ratio and Cancer Prognosis: An Umbrella Review Trends Immunol (2019) 40:228. doi: 10.1016/j.it.2019.01.006

11. Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors. Nat Rev Clin Oncol (2021) 18:345–62. doi: 10.1038/s41571-021-00473-5

12. Zhou G, Sprengers D, Boor PPC, Doukas M, Schütz H, Mancham S, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology (2017) 153:1107–1119.e1. doi: 10.1053/j.gastro.2017.06.017

13. Liu XS, Lin XK, Mei Y, Ahmad S, Yan CX, Jin HL, et al. Regulatory T Cells (+) T Cells in Resected Hepatocellular Carcinoma Prolong Patient Survival. J Hepatol (2015) 63:313–20. doi: 10.1016/j.jhep.2014.02.003

14. Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, et al. Tumor-Infiltrating, Interleukin-33-Producing Effector-Memory CD8+ T Cells in Resected Hepatocellular Carcinoma Prolong Survival. Gastroenterology (2014) 146:206–21. doi: 10.1053/j.gastro.2017.04.010

15. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends Mol Med (2019) 40:310–27. doi: 10.1016/j.it.2019.02.003
Immunosuppression by Tr1 Cells in Human Liver Tumors. *Oncoimmunology* (2015) 4:e1008355. doi: 10.1080/2162402x.2015.1008355

41. Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, et al. Trm-1 Fosters HCC Development by Enhancing TGF-β-Beta-Mediated Alternative Activation of Macrophages. *Gut* (2015) 64:1593–604. doi: 10.1136/gutjnl-2014-307671

42. Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of Pre and Post-Operative Models to Predict Early Recurrence of Hepatocellular Carcinoma After Surgical Resection. *J Hepatol* (2018) 69:1284–93. doi: 10.1016/j.jhep.2018.08.027

43. Sudo T, Nishida R, Kawahara A, Saisho K, Mimori K, Yamada A, et al. Clinical Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. *Cancer Res* (2017) 77:3540–50. doi: 10.1158/0008-5472.can-16-3556

44. Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, et al. Immune-Related Gene Expression Profiling After PD-1 Inhibition in Non-Small Cell Lung Carcinoma. *Ann Surg Oncol* (2017) 24:3763–70. doi: 10.1245/s10434-017-5796-4

45. Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, et al. Immune-Related Gene Expression Profiling After PD-1 Inhibition in Non-Small Cell Lung Carcinoma. *Ann Surg Oncol* (2017) 24:3763–70. doi: 10.1245/s10434-017-5796-4

46. Chen AW, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of Pre and Post-Operative Models to Predict Early Recurrence of Hepatocellular Carcinoma After Surgical Resection. *J Hepatol* (2018) 69:1284–93. doi: 10.1016/j.jhep.2018.08.027

47. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. *JAMA Oncol* (2016) 34:1223–30. doi: 10.1001/jco.2015.630970

48. Adams S, Gray RJ, Demonia S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. *J Clin Oncol* (2016) 34:2939–56. doi: 10.1200/JCO.2015.55.0491

49. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene Expression Analysis of Macrophages That Facilitate Tumor Invasion Supports a Role for Wnt- and TGF-Beta-Mediated Alternative Activation of Macrophages. *Gut* (2015) 64:1593–604. doi: 10.1136/gutjnl-2014-307671

50. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast Cancer Trios: ECOG 2197 and ECOG 1199. *Clin Oncol* (2016) 34:1223–30. doi: 10.1001/jco.2015.630970

51. Roberts NJ, Zhou S, Diaz LA Jr., Holdhoff M. Systemic Use of Tumor Necrosis Factor Alpha as an Anticancer Agent. *Oncotarget* (2016) 7:2739–51. doi: 10.18632/oncotarget.344

52. Dalton DK, Noelle RJ. The Roles of Mast Cells in Anticancer Immunity. *Cancer Immunol Immunother* (2012) 61:1511–20. doi: 10.1007/s00262-012-1246-0

53. Varricchi G, Galldieiro MR, Marone G, Granata F, Borriello F, Marone G. Controversial Role of Mast Cells in Skin Cancers. *Exp Dermatol* (2017) 26:11–7. doi: 10.1111/exd.13107

54. Mukai K, Tsai M, Saito H, Galli SJ. Mast Cells as Sources of Cytokines, Chemokines, and Growth Factors. *Immunol Rev* (2018) 282:121–50. doi: 10.1111/imr.12634

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wan, Lu, Xu, Yuan, Xiao, Xie and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.